Celldex Therapeutics (CLDX) Receives News Sentiment Rating of 0.10

Headlines about Celldex Therapeutics (NASDAQ:CLDX) have been trending somewhat positive on Monday, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celldex Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 47.0999720868937 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have effected Accern’s analysis:

Celldex Therapeutics (NASDAQ CLDX) opened at $2.91 on Monday. Celldex Therapeutics has a one year low of $2.20 and a one year high of $4.07.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.07. The company had revenue of $3.90 million for the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. Celldex Therapeutics’s revenue was up 77.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.29) earnings per share. equities analysts predict that Celldex Therapeutics will post -0.93 earnings per share for the current year.

A number of brokerages recently issued reports on CLDX. ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. HC Wainwright restated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $6.31.

COPYRIGHT VIOLATION NOTICE: “Celldex Therapeutics (CLDX) Receives News Sentiment Rating of 0.10” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/04/celldex-therapeutics-cldx-receives-news-sentiment-rating-of-0-10.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

What are top analysts saying about Celldex Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celldex Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit